Mazama Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Mazama Capital Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-11,139	Closed	-$701K	–	297
2015 Q2	$701K	Sell	11,139 -23,136	-68%	-$1.26M	0.14%	152
2015 Q1	$1.65M	Sell	34,275 -43,889	-56%	-$1.68M	0.34%	89
2014 Q4	$2.6M	Buy	78,164 +55,352	+243%	+$1.8M	0.6%	56
2014 Q3	$669K	Buy	22,812 +11,354	+99%	+$377K	0.17%	154
2014 Q2	$445K	Buy	11,458 +9,815	+597%	+$398K	0.12%	184
2014 Q1	$69K	Sell	1,643 -877	-35%	-$36.6K	0.06%	110
2013 Q4	$83K	Sell	2,520 -1,135	-31%	-$37K	0.04%	158
2013 Q3	$99K	Buy	+3,655	New	+$103K	0.05%	138

Other funds holding LGND

RIM

RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DMK

David M. Knott $275M AUM 59.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ORI

Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Mazama Capital Management's LGND Position: Q3 2015 in Review

Mazama Capital Management sold out of Ligand Pharmaceuticals (LGND) in Q3 2015, closing a stake of 11,139 shares — an estimated $701K sold.

Mazama Capital Management first reported a position in LGND in Q3 2013 and held it in 8 quarters. The position peaked at $2.6M in Q4 2014. 203 funds tracked by Wall St. Rank hold LGND as of Q3 2015.

Mazama Capital Management reported no remaining Ligand Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
Mazama Capital Management sold 11,139 Ligand Pharmaceuticals shares in Q3 2015, an estimated $701K.
Mazama Capital Management first reported a position in Ligand Pharmaceuticals in Q3 2013 and held it in 8 quarters.
Mazama Capital Management's Ligand Pharmaceuticals position peaked at $2.6M in Q4 2014.
203 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2015.

Based on Mazama Capital Management's 13F filing for Q3 2015, filed 13 Nov 2015.